Atogepant 60 mg
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine, Chronic Migraine
Trial Timeline
Feb 19, 2021 → Oct 20, 2025
NCT ID
NCT04686136About Atogepant 60 mg
Atogepant 60 mg is a phase 3 stage product being developed by AbbVie for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT04686136. Target conditions include Episodic Migraine, Chronic Migraine.
What happened to similar drugs?
3 of 15 similar drugs in Episodic Migraine were approved
Approved (3) Terminated (1) Active (11)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04686136 | Phase 3 | Completed |
| NCT04437433 | Phase 3 | Completed |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 44 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| BOTOX + Placebo | AbbVie | Phase 3 | 32 |
| Atogepant + Ubrogepant | AbbVie | Approved | 43 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 47 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 43 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 40 |
| Erenumab | Novartis | Phase 3 | 40 |
| Placebo + AMG 301 | Amgen | Phase 2 | 35 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 29 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 41 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 39 |
| Methylprednisolone | Brain Biotech | Approved | 33 |